An active Ebola outbreak in the Democratic Republic of the Congo has prompted a new U.S. financial commitment toward developing targeted medical tools against the specific viral strain driving the crisis. On June 12, 2026, the U.S. Department of State announced its intent to provide $50 million to the Coalition for Epidemic Preparedness Innovations (CEPI), working in coordination with Congress, to advance medical countermeasures against the Bundibugyo strain of Ebola, the strain responsible for the current outbreak. The funding would support laboratory studies, clinical trials, and manufacturing for Bundibugyo countermeasure candidates.
The announcement brings the State Department’s total direct Ebola response funding to more than $270 million. That figure is separate from $350 million in humanitarian assistance directed to the DRC, South Sudan, and Uganda, itself part of a broader $1.8 billion commitment to the UN Office for the Coordination of Humanitarian Affairs announced in May. The State Department describes the United States as the largest financial contributor to the current Ebola response, with efforts coordinated alongside the U.S. Centers for Disease Control and Prevention (CDC) and partner governments in the region.
The Bundibugyo strain is a distinct Ebola species for which no licensed vaccine or therapeutic currently exists, setting it apart from the Zaire strain that has been the focus of most prior countermeasure development. Investing in Bundibugyo-specific tools addresses a recognized gap in the global health security toolkit. Without effective countermeasures tailored to the circulating strain, outbreak containment relies almost entirely on non-pharmaceutical interventions such as contact tracing, isolation, and safe burial practices, which are resource-intensive and difficult to sustain at scale in conflict-affected or low-infrastructure settings.
A Pledge at Odds with the Domestic Funding Landscape
The pledge is welcome news for global health security professionals, but it arrives in sharp tension with the administration’s broader domestic health funding posture. The White House FY2027 budget request, released April 4, 2026, proposes cutting the Biomedical Advanced Research and Development Authority (BARDA) by nearly $395.5 million, reducing its budget to $654.4 million. BARDA is the primary federal engine for medical countermeasure development and the domestic institutional counterpart to international bodies like CEPI; it funds the research, development, and procurement pipeline that moves countermeasure candidates from laboratory to stockpile. The same budget proposal would reduce the Strategic National Stockpile by $61.8 million, cut Project BioShield by $125 million, and eliminate the Hospital Preparedness Program entirely. The Administration for Strategic Preparedness and Response (ASPR), the HHS component that houses BARDA and coordinates the federal emergency health response, would see its total budget fall by approximately $356 million from FY2026 enacted levels.
Those proposed cuts compound a separate policy shift that experts have flagged as a preparedness vulnerability. In August 2025, HHS cancelled hundreds of millions of dollars in federal investment in mRNA vaccine development, a platform widely considered the leading candidate technology for rapid countermeasure development against novel or re-emerging pathogens because of its speed and adaptability. Critics note that the United States remains heavily dependent on egg-based vaccine production, a system already under strain from H5N1-related poultry culls that threaten both food and vaccine supply chains.
It is worth noting that the president’s budget is a policy statement, not law. Congress retains authority over appropriations, and lawmakers have previously demonstrated willingness to reject similar proposals. The FY2026 budget request included comparable cuts to CDC and NIH, most of which did not survive the final funding process. Nevertheless, the sustained pressure on preparedness budgets, combined with the departure from mRNA investment, has generated significant concern among public health professionals about the durability of U.S. countermeasure capacity over the longer term.
Response Operations on the Ground
On the ground in the DRC, the scale of the response is becoming clearer. U.S.-funded implementer International Medical Corps has screened more than 6,300 individuals across 24 health facilities in Ituri Province, identifying 41 suspected Ebola cases for isolation as of June 8. Medair and IMC together support 100 health facilities in affected areas, including six specialized Ebola treatment centers. Bed capacity has emerged as a critical constraint, and work is underway to establish additional treatment facilities in the Ituri towns of Bunia and Nyankunde.
Safe and dignified burials are a cornerstone of Ebola response given the high viral load present in deceased individuals. FHI 360 and the International Federation of the Red Cross and Red Crescent Societies are leading this effort; as of June 11, IFRC had completed 200 such burials using 15 combined teams. Engagement with local religious and community leaders is ongoing to expand acceptance of safe burial practices, which can face cultural resistance in affected communities.
Sources and Further Information:
Ebola Response Update – June 12, 2026 – U.S. Department of State
FY 2027 President’s Budget Request: ASPR Highlights – HHS
HHS Winds Down mRNA Vaccine Development Under BARDA (Aug 2025) – HHS ASPR
Abandoning mRNA: Why HHS’ Vaccine Retreat Puts Public Health Security at Risk – Global Biodefense
White House FY2027 Budget Would Cut CDC Funding by 40%, Eliminate Dozens of Public Health Programs – Global Biodefense